Rottapharm launches high-speed bookbuilding
Italian pharmaceuticals firm Rottapharm launched bookbuilding for a €450m IPO on Wednesday, aiming to find a premium to the sector and running a shorter bookbuilding period than normal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts